

Novel injectable TRAP-Paclitaxel chemotherapeutic for Equine Eyelid Squamous cell carcinoma

Recruiting for Clinical trial:

- \$5000 available for patients (biopsy and treatment)

Purpose: Assess treatment outcome of injectable chemotherapeutic (paclitaxel) linked to novel anchoring technology called Tissue Reactive Anchoring Pharmaceuticals (TRAP) in equine eyelid SCC.

- TRAP allows for sustained drug release.

Inclusion criteria:

- Focal eyelid SCC (1-2 sites, longest diameter ≥ 10 mm)
- Histopathologic confirmation of SCC

For more info, please contact:

Dr. Annie Oh, DVM, MS, DACVO
Assistant Professor, Ophthalmology
aoh@ncsu.edu

